BIBR 1532 is an effective, specific and non-competitive telomerase inhibitor (IC50: 100 nM, in a cell-free assay).

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

BIBR-1532；BIBR1532

powder

DMSO : 33.1 mg/mL (100 mM)

Ethanol : 8.3 mg/mL (25 mM)

Telomerase

BIBR 1532 non-competitively inhibits telomerase activity. BIBR 1532 inhibits the proliferation of JVM13 leukemia cells with an IC50 of 52 μM, and similar effect also occurs in other leukemia cell lines such as Nalm-1, HL-60, and Jurkat. BIBR 1532 exerts antiproliferative effect on acute myeloid leukemia (AML) with IC50 of 56 μM with no effect on the proliferative capacity of normal hematopoietic progenitor cells. BIBR 1532 (2.5 μM) reduces colony-forming ability, induces telomere length shortening and causes chemotherapeutic sensitization via inhibiting telomerase activity in MCF-7/WT and melphalan-resistant MCF-7/MlnR cell lines. BIBR 1532 is cytotoxic in a dose-dependent manner in T-cell prolymphocytic leukemia (T-PLL). BIBR 1532 in combination with carboplatin (a chemotherapeutic agent) eliminates ovarian cancer spheroid-forming cells in ES2, SKOV3, and TOV112D cell lines.

[1] Pascolo E, et al. J Biol Chem. 2002, 277(18), 15566-15572.
[2] Barma, D.K., et al. 2003. Bioorg. Med. Chem. Lett. 13: 1333-1336.
[3] Rankin, A.M., et al. 2008. Anticancer Drugs. 19: 329-338.
[4] Parsch, D., et al. 2008. Cancer Invest. 26: 590-596.